See more : tokentus investment AG (14D.DE) Income Statement Analysis – Financial Results
Complete financial analysis of China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China Resources Boya Bio-pharmaceutical Group Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Emerge Commerce Ltd. (EMCMF) Income Statement Analysis – Financial Results
- Bradespar S.A. (BRAP3.SA) Income Statement Analysis – Financial Results
- Fujian Yuanli Active Carbon Co.,Ltd. (300174.SZ) Income Statement Analysis – Financial Results
- Kangmei Pharmaceutical Co., Ltd. (600518.SS) Income Statement Analysis – Financial Results
- Landmark Cars Limited (LANDMARK.BO) Income Statement Analysis – Financial Results
China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ)
About China Resources Boya Bio-pharmaceutical Group Co., Ltd.
China Resources Boya Bio-pharmaceutical Group Co., Ltd. engages in the blood products, diabetes medication, biochemical medication, and chemical medicine businesses in China. It engages in the research and development, production, and sales of blood products comprising human fibrinogen, intravenous human immunoglobulin, rabies immunoglobulin, human albumin, human immunoglobulin, freeze-dried intravenous human immunoglobulin, and hepatitis B human immunoglobulin; diabetes products, including metformin hydrochloride tablets/enteric-coated tablets, pioglitazone hydrochloride dispersible tablets, glimepiride tablets, and calcium dobesilate capsules; and compound osteotide, oxytocin, and heparin sodium injections for various fields, such as medicine, hepatitis, gynecology, and immunomodulation. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co., Ltd. China Resources Boya Bio-pharmaceutical Group Co., Ltd. was founded in 1993 and is based in Fuzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.65B | 2.76B | 2.65B | 2.51B | 2.76B | 2.39B | 1.46B | 946.60M | 543.18M | 437.79M | 245.28M | 227.26M | 196.72M | 141.82M | 119.72M | 90.17M |
| Cost of Revenue | 1.25B | 1.25B | 1.14B | 1.05B | 976.57M | 863.30M | 491.24M | 349.89M | 194.95M | 167.59M | 106.27M | 93.19M | 70.69M | 41.73M | 38.19M | 29.95M |
| Gross Profit | 1.40B | 1.51B | 1.51B | 1.46B | 1.78B | 1.52B | 969.29M | 596.71M | 348.23M | 270.20M | 139.00M | 134.07M | 126.03M | 100.10M | 81.54M | 60.22M |
| Gross Profit Ratio | 52.76% | 54.66% | 56.98% | 58.07% | 64.63% | 63.84% | 66.37% | 63.04% | 64.11% | 61.72% | 56.67% | 59.00% | 64.06% | 70.58% | 68.10% | 66.79% |
| Research & Development | 80.95M | 49.58M | 59.29M | 89.05M | 92.76M | 45.06M | 34.53M | 42.41M | 23.89M | 16.64M | 14.22M | 11.06M | 8.87M | 9.08M | 6.81M | 0.00 |
| General & Administrative | 49.06M | 41.04M | 59.37M | 58.87M | 60.54M | 52.34M | 39.81M | 45.82M | 30.98M | 26.01M | 18.85M | 24.18M | 19.01M | 13.12M | 12.93M | 19.10M |
| Selling & Marketing | 538.81M | 697.28M | 770.35M | 866.24M | 963.56M | 754.59M | 377.93M | 113.41M | 75.87M | 64.49M | 7.73M | 7.87M | 6.55M | 5.74M | 4.42M | 2.42M |
| SG&A | 777.23M | 738.32M | 829.72M | 925.12M | 1.02B | 806.93M | 417.74M | 159.23M | 106.85M | 90.51M | 26.58M | 32.05M | 25.57M | 18.86M | 17.36M | 21.52M |
| Other Expenses | 179.88M | -179.01K | 10.78M | -3.33M | 5.92M | 7.71M | 1.25M | 2.89M | 6.20M | 6.71M | 3.93M | -5.39M | 8.33M | 6.38M | 665.56K | -15.78M |
| Operating Expenses | 1.04B | 985.60M | 1.04B | 1.13B | 1.25B | 947.90M | 554.20M | 280.24M | 186.41M | 145.37M | 62.20M | 62.96M | 51.39M | 41.79M | 35.94M | 22.46M |
| Cost & Expenses | 2.30B | 2.24B | 2.18B | 2.18B | 2.22B | 1.81B | 1.05B | 630.13M | 381.36M | 312.96M | 168.48M | 156.15M | 122.09M | 83.52M | 74.13M | 52.41M |
| Interest Income | 31.29M | 26.20M | 31.50M | 12.82M | 13.93M | 16.59M | 10.92M | 10.36M | 8.41M | 10.79M | 17.15M | 12.61M | 556.11K | 703.50K | -0.10 | -0.96 |
| Interest Expense | 800.54K | 622.91K | 10.53M | 21.45M | 30.76M | 23.98M | 1.54M | 349.01K | 1.12M | 187.14K | 73.42K | 1.07M | 3.66M | 5.75M | 2.72M | 4.21M |
| Depreciation & Amortization | 113.91M | 110.72M | 112.98M | 94.60M | 93.94M | 67.03M | 52.29M | 49.80M | 29.95M | 26.88M | 19.18M | 17.62M | 16.53M | 17.09M | 7.25M | 3.75M |
| EBITDA | 468.42M | 643.64M | 552.65M | 436.28M | 631.82M | 667.83M | 490.78M | 378.33M | 228.66M | 162.97M | 116.88M | 107.34M | 96.89M | 82.12M | 52.85M | 37.76M |
| EBITDA Ratio | 17.66% | 24.78% | 24.26% | 17.29% | 23.24% | 28.07% | 33.33% | 39.61% | 42.20% | 37.66% | 47.73% | 47.26% | 49.25% | 58.16% | 44.94% | 41.75% |
| Operating Income | 355.23M | 532.18M | 443.06M | 331.46M | 514.12M | 564.54M | 429.36M | 325.66M | 192.29M | 129.39M | 93.83M | 82.56M | 71.64M | 53.58M | 42.53M | 33.90M |
| Operating Income Ratio | 13.39% | 19.29% | 16.72% | 13.19% | 18.62% | 23.65% | 29.40% | 34.40% | 35.40% | 29.56% | 38.26% | 36.33% | 36.42% | 37.78% | 35.52% | 37.59% |
| Total Other Income/Expenses | -1.51M | -179.01K | 61.39K | -3.33M | 5.92M | 7.71M | 1.25M | 2.58M | 7.98M | 6.52M | 3.93M | 6.10M | 5.19M | 666.06K | -2.48M | -15.78M |
| Income Before Tax | 353.71M | 532.00M | 443.12M | 328.13M | 520.04M | 572.24M | 430.61M | 328.15M | 197.59M | 135.91M | 97.76M | 88.66M | 76.83M | 59.28M | 42.65M | 18.12M |
| Income Before Tax Ratio | 13.34% | 19.28% | 16.72% | 13.06% | 18.84% | 23.97% | 29.48% | 34.67% | 36.38% | 31.04% | 39.86% | 39.01% | 39.06% | 41.80% | 35.63% | 20.09% |
| Income Tax Expense | 105.56M | 86.51M | 84.84M | 52.87M | 77.92M | 87.16M | 65.68M | 50.60M | 30.55M | 20.71M | 15.40M | 13.51M | 11.60M | 9.30M | 11.15M | 7.46M |
| Net Income | 237.47M | 432.20M | 344.53M | 260.06M | 426.15M | 469.17M | 356.59M | 272.04M | 151.80M | 104.18M | 82.40M | 75.15M | 65.23M | 49.98M | 31.48M | 10.71M |
| Net Income Ratio | 8.95% | 15.67% | 13.00% | 10.35% | 15.43% | 19.65% | 24.42% | 28.74% | 27.95% | 23.80% | 33.60% | 33.07% | 33.16% | 35.24% | 26.29% | 11.88% |
| EPS | 0.47 | 0.86 | 0.79 | 0.61 | 1.00 | 1.11 | 0.89 | 1.02 | 0.44 | 0.31 | 0.24 | 0.24 | 0.26 | 0.20 | 0.14 | 0.05 |
| EPS Diluted | 0.47 | 0.86 | 0.79 | 0.61 | 1.00 | 1.11 | 0.89 | 1.02 | 0.44 | 0.31 | 0.24 | 0.24 | 0.26 | 0.20 | 0.14 | 0.05 |
| Weighted Avg Shares Out | 505.25M | 504.25M | 436.11M | 425.94M | 426.15M | 422.68M | 400.66M | 266.71M | 343.87M | 339.72M | 340.20M | 319.02M | 255.26M | 255.56M | 217.93M | 200.87M |
| Weighted Avg Shares Out (Dil) | 505.25M | 504.25M | 436.11M | 425.94M | 426.15M | 422.68M | 400.66M | 266.71M | 345.00M | 339.72M | 340.20M | 319.02M | 255.26M | 255.56M | 217.93M | 200.87M |
Source: https://incomestatements.info
Category: Stock Reports